Mark Levin Insider Profile
4 Followers
Mark Levin, Director, Ten Percent Owner at Fulcrum Therapeutics, holds 4.05M shares in Fulcrum Therapeutics (Ticker: FULC), holds 6.43M shares in Voyager Therapeutics (Ticker: VYGR), holds 3.56M shares in Blueprint Medicines (Ticker: BPMC).
Mark Levin's Trading History
| FULCFulcrum Therapeutics | Nov 12, 2021 | Director, Ten Percent Owner | Uninformative Sell | ― | $15.26M | |
| VYGRVoyager Therapeutics | Sep 19, 2018 | Director | Uninformative Sell | ― | $11.12M | |
| BPMCBlueprint Medicines | Mar 20, 2017 | ― | Informative Sell | 1.23M | $461.52M | |
| FMIFoundation Medicine | May 12, 2014 | ― | Uninformative Buy | ― | $2.39M | |
| CARMCarisma Therapeutics | ― | Director | ― | $0.00 |
You May Also Like
Mark Levin insider profile FAQ
What is the percentage of profitable transactions made by Mark Levin?
The percentage of profitable transactions made by Mark Levin is 50%.
What is the average return per transaction made by Mark Levin?
The average return per transaction made by Mark Levin is -54.10%.
What stocks does Mark Levin hold?
Mark Levin holds: FULC, FMI, BPMC, VYGR, CARM stocks.
What was Mark Levin's most profitable transaction?
Mark Levin’s most profitable transaction was an Informative Buy of FULC stock on July 22, 2019. The return on the trade was 39.20%.
What is Mark Levin's role in Fulcrum Therapeutics?
Mark Levin's role in Fulcrum Therapeutics is Director, Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.
